

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, the company noted during consultation that comparators Cinryze and Berinert are derived from human plasma, which some religious groups may be unwilling to be treated with. It further added that garadacimab is not directly extracted from human serum or plasma.

A stakeholder also noted that a possible inequality that would exist is the availability within individual NHS Trusts to prescribe this medication.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Where appropriate, the committee may consider garadacimab compared with alternative comparators for people who cannot take those that are derived from human plasma.

The availability within individual trusts to prescribe garadacimab, should it be recommended, is an implementation issue. Implementation issues cannot be addressed in a technology appraisal recommendation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): Ross Dent

Date: 26/08/2024